Submissions from 2019
The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC., Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew Muir, Simon Rushbrook, Xiaomin Lu, Jun Xu, Jen-Chieh Chuang, Andrew N Billin, Chuhan Chung, Georgia Li, G Mani Subramanian, Robert P Myers, Christopher L Bowlus, and Kris V Kowdley
A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence after Liver Transplantation: The RH-IML Classification., Philip Vutien, Jennifer Dodge, Kiran M Bambha, Eric M Nordstrom, Jane Gralla, Kristen Campbell, Claire Levek, Trevor Nydam, Oren Fix, George Ioannou, and Scott W Biggins
A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification., Philip Vutien, Jennifer Dodge, Kiran M Bambha, Eric M Nordstrom, Jane Gralla, Kristen Campbell, Claire Levek, Trevor Nydam, Oren K Fix, George Ioannou, and Scott W Biggins
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial., Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome, David Sheridan, Muhammad Y Sheikh, James Trotter, Whitfield Knapple, Eric Lawitz, Manal F Abdelmalek, Kris V Kowdley, Aldo J Montano-Loza, Jerome Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh MacConell, Reshma Shringarpure, Stephen Harrison, and Arun J Sanyal
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial., Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome, David Sheridan, Muhammad Y Sheikh, James Trotter, Whitfield Knapple, Eric Lawitz, Manal F Abdelmalek, Kris V Kowdley, Aldo J Montano-Loza, Jerome Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh MacConell, Reshma Shringarpure, Stephen Harrison, and Arun J Sanyal
Submissions from 2018
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis., Tarik Asselah, Kris V Kowdley, Neddie Zadeikis, Stanley Wang, Tarek Hassanein, Yves Horsmans, Massimo Colombo, Filipe Calinas, Humberto Aguilar, Victor de Ledinghen, Parvez S Mantry, Christophe Hezode, Rui Tato Marinho, Kosh Agarwal, Frederik Nevens, Magdy Elkhashab, Jens Kort, Ran Liu, Teresa I Ng, Preethi Krishnan, Chih-Wei Lin, and Federico J Mensa
Complement Factor D protects mice from ethanol-induced inflammation and liver injury., Rebecca L McCullough, Megan R McMullen, Megan M Sheehan, Kyle L Poulsen, Sanjoy Roychowdhury, Dian J Chiang, Michele T Pritchard, Juan Caballeria, and Laura E Nagy
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO., Zobair M Younossi, Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, William R Lenderking, Anne Skalicky, Leah Kleinman, Robert P Myers, G Mani Subramanian, John G McHutchison, Cynthia Levy, Christopher L Bowlus, Kris V Kowdley, and Andrew J Muir
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis., Zobair M Younossi, Rohit Loomba, Quentin M Anstee, Mary E Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H Caldwell, Vlad Ratziu, Kathleen E Corey, Scott L Friedman, Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal, Joel E Lavine, Philippe Mathurin, Michael R Charlton, Zachary D Goodman, Naga P Chalasani, Kris V Kowdley, Jacob George, and Keith Lindor
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis., Zobair M Younossi, Rohit Loomba, Mary E Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H Caldwell, Vlad Ratziu, Kathleen E Corey, Scott L Friedman, Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal, Joel E Lavine, Philippe Mathurin, Michael R Charlton, Naga P Chalasani, Quentin M Anstee, Kris V Kowdley, Jacob George, Zachary D Goodman, and Keith Lindor
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir., Zobair M Younossi, Maria Stepanova, Stuart Gordon, Stefan Zeuzem, Michael P Mann, Ira Jacobson, Marc Bourliere, Curtis Cooper, Steven Flamm, K Rajender Reddy, Kris V Kowdley, Issah Younossi, and Sharon Hunt
Submissions from 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection., Marc Bourlière, Stuart C Gordon, Steven L Flamm, Curtis L Cooper, Alnoor Ramji, Myron Tong, Natarajan Ravendhran, John M Vierling, Tram T Tran, Stephen Pianko, Meena B Bansal, Victor de Lédinghen, Robert H Hyland, Luisa M Stamm, Hadas Dvory-Sobol, Evguenia Svarovskaia, Jie Zhang, K C Huang, G Mani Subramanian, Diana M Brainard, John G McHutchison, Elizabeth C Verna, Peter Buggisch, Charles S Landis, Ziad H Younes, Michael P Curry, Simone I Strasser, Eugene R Schiff, K Rajender Reddy, Michael P Manns, Kris V Kowdley, and Stefan Zeuzem
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis., Blaire E Burman, Manan A Jhaveri, and Kris V Kowdley
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients., M P Curry, E B Tapper, B Bacon, D Dieterich, S L Flamm, L Guest, K V Kowdley, Y Lee, S Milligan, N Tsai, Z Younossi, and N H Afdhal
Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis., Priya Handa, Akhila L Vemulakonda, Bryan D Maliken, Vicki Morgan-Stevenson, James E Nelson, Barjinder K Dhillon, Kelly A Hennessey, Rohit Gupta, Matthew M Yeh, and Kris V Kowdley
Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease., Christine C Hsu, Erik Ness, and Kris V Kowdley
New developments in the treatment of primary biliary cholangitis - role of obeticholic acid., Manan A Jhaveri and Kris V Kowdley
The Natural History of Severe Acute Liver Injury., David G Koch, J L Speiser, V Durkalski, R J Fontana, T Davern, B McGuire, R T Stravitz, A M Larson, I Liou, Oren K Fix, M L Schilsky, T McCashland, J E Hay, N Murray, O S Shaikh, D Ganger, A Zaman, S B Han, R T Chung, R S Brown, S Munoz, K R Reddy, L Rossaro, R Satyanarayana, A J Hanje, J Olson, R M Subramanian, C Karvellas, B Hameed, A H Sherker, W M Lee, and A Reuben
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection., Kris V Kowdley, Vinay Sundaram, Christie Y Jeon, Kamran Qureshi, Nyan L Latt, Amandeep Sahota, Stephen Lott, Michael P Curry, Naoky Tsai, Nathorn Chaiyakunapruk, Yoori Lee, Jorg Petersen, and Peter Buggisch
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir., David Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, Brian P Doehle, Ross Martin, Nezam H Afdhal, Kris V Kowdley, Eric Lawitz, Diana M Brainard, Michael D Miller, Hongmei Mo, and Edward J Gane
